Know Cancer

or
forgot password

Feasibility of Using the GlowCap Reminder System in Patients With Early Stage Breast Cancer Receiving Adjuvant Endocrine Therapy


N/A
60 Years
N/A
Not Enrolling
Female
Breast Cancer

Thank you

Trial Information

Feasibility of Using the GlowCap Reminder System in Patients With Early Stage Breast Cancer Receiving Adjuvant Endocrine Therapy


Inclusion Criteria:



- Early stage breast cancer patients taking adjuvant endocrine therapy (ie, tamoxifen,
anastrozole, letrozole, exemestane).

- Age ≥ 60 years

- Must have broadband internet access at home (to enable the base for the system to
communicate to the Vitality server).

- Must have a landline or mobile phone

Exclusion Criteria:

- Non-English speaking patients

Type of Study:

Observational

Study Design:

Observational Model: Case-Only, Time Perspective: Prospective

Outcome Measure:

Assess the usability of the GlowCap system by patients

Outcome Description:

>60 years of age with early stage breast cancer.

Outcome Time Frame:

2 years

Safety Issue:

No

Principal Investigator

Tiffany Traina, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Memorial Sloan-Kettering Cancer Center

Authority:

United States: Institutional Review Board

Study ID:

10-183

NCT ID:

NCT01239251

Start Date:

November 2010

Completion Date:

November 2012

Related Keywords:

  • Breast Cancer
  • GlowCap
  • adjuvant endocrine therapy
  • Breast Neoplasms

Name

Location

Memorial Sloan-Kettering Cancer Center 1275 York AvenueNew York, New York  10021